Compare FSP & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | ANVS |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 60.1M |
| IPO Year | 2001 | 2019 |
| Metric | FSP | ANVS |
|---|---|---|
| Price | $0.64 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 270.3K | ★ 1.4M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | 15.69 | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $1.42 |
| 52 Week High | $1.88 | $5.50 |
| Indicator | FSP | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 50.44 |
| Support Level | $0.58 | $1.92 |
| Resistance Level | $0.71 | $2.99 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 36.15 | 97.30 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.